Understanding Open Access Policies in Clinical Trial Publishing

Introduction: The Rise of Open Access in Clinical Research

Open access (OA) publishing is transforming the way clinical trial results are shared with the global scientific community and the public. Traditionally, medical journals operated on subscription-based models, limiting the visibility of research. Today, funders, regulators, and journals are driving an unprecedented shift toward open access—making clinical trial data more accessible, transparent, and reusable.

Open access is not just about free reading. It involves rights for reuse, public archiving, and in many cases, funder compliance. In this article, we’ll explore the major open access models, policies of leading medical journals, and implications for trial sponsors and investigators aiming for transparent publication of their clinical data.

Types of Open Access: Gold, Green, and Hybrid

There are three core models of open access relevant to trial publications:

• Gold OA: Articles are made immediately available by the publisher under an open license (e.g., Creative Commons). Authors or sponsors usually pay an Article Processing Charge (APC).
• Green OA: Authors self-archive a preprint or postprint version in an institutional or subject repository (e.g., Europe PMC), typically after an embargo period.
• Hybrid OA: Subscription-based journals offer individual OA options for an APC while keeping other content behind paywalls.

Understanding these models helps researchers select suitable journals that align with sponsor or regulatory OA requirements, such as the European Union’s Horizon 2020/Europe mandate or NIH’s Public Access Policy.

OA Policies of Leading Medical Journals

Each major medical journal or publisher has its own open access policy. Here is a comparative overview of key players:

Before submission, authors should review individual journal policies, which are often detailed under “Instructions for Authors” or “Open Access” sections.

Funder and Institutional OA Requirements

Funding agencies increasingly mandate open access to published trial results. Notable examples include:

• NIH (USA): Requires deposition in PubMed Central within 12 months.
• Horizon Europe: Immediate gold OA with CC BY licensing required.
• Wellcome Trust: Supports full gold OA with APC coverage.
• Bill & Melinda Gates Foundation: Mandates immediate OA via PubMed Central or equivalent.
• WHO: Strongly encourages OA publication for all WHO-funded trials.

Non-compliance can affect future funding eligibility or trigger audits. Clinical teams should plan publication strategies in alignment with funder policies during trial planning stages.

Plan S and Its Impact on Trial Publishing

Plan S is an international OA initiative requiring all scholarly publications funded by cOAlition S members to be published in compliant open access journals or platforms. It affects trial sponsors in the EU, UKRI (UK), and some global health agencies.

Plan S compliance requires:

• Immediate availability (no embargo)
• Publishing under a CC BY license
• Disclosure of all fees (transparency in APCs)

Many major journals now offer Plan S-compliant routes, but authors must verify compliance before submission.

Managing APCs and Sponsor Budgeting

Article Processing Charges (APCs) can be significant—ranging from $1,500 to over $10,000 depending on the journal. Trial sponsors should:

• Include APCs in trial budgets from the outset
• Negotiate institutional discounts or use transformative agreements
• Prioritize journals with tiered pricing for LMIC authors if applicable

Some publishers (e.g., Springer Nature, Elsevier) have national-level deals that waive or reduce APCs for researchers in certain countries or institutions.

Transparency Beyond Access: Data and Protocols

Modern OA policies increasingly extend beyond the article to include:

• Trial Protocols: Published as supplementary material or in protocol journals (e.g., BMJ Open)
• Datasets: Linked to repositories like Dryad, Figshare, or institutional databases
• Analysis Code: Shared via GitHub or repositories with DOIs

This reinforces reproducibility and is encouraged under ICMJE and SPIRIT guidelines. Some journals require a Data Availability Statement or Data Sharing Statement per ICMJE.

Choosing the Right Journal: Key Considerations

Before submission, evaluate journals using the following criteria:

• OA policy and licensing terms
• Indexing in PubMed, DOAJ, Scopus, etc.
• Impact Factor and readership relevance
• Funder compliance (Plan S, NIH, Gates)
• Costs and APC waivers

Resources like the Journal Checker Tool help match journals with funder mandates and OA routes.

Conclusion: Open Access is Now a Regulatory and Ethical Norm

The shift to open access in clinical trial publishing is not just a publishing trend—it’s a compliance imperative. Sponsors and investigators must now navigate funder rules, licensing standards, APC costs, and journal requirements to ensure that trial results reach the public without barriers.

By planning early, selecting journals strategically, and aligning with global transparency norms, research teams can meet ethical obligations, enhance visibility, and ensure continued eligibility for funding and regulatory goodwill.

How to Choose Between Open Access and Subscription-Based Journals for Clinical Manuscripts

One of the most critical decisions for clinical trial professionals and medical writers is choosing the right journal for manuscript submission. With the growth of scientific publishing, authors must navigate between open access (OA) and subscription-based journals. Each option has unique advantages and trade-offs related to accessibility, visibility, cost, and compliance.

This guide walks you through how to evaluate and select the most appropriate publishing model based on your research goals, target audience, sponsor requirements, and journal characteristics. It aligns with evolving expectations from regulators like EMA for greater transparency and public availability of clinical trial data.

Understanding the Two Publishing Models:

Open Access Journals:

OA journals make articles freely available to all readers without subscription. Authors usually pay an Article Processing Charge (APC).

• Free public access immediately upon publication
• High visibility and global reach
• Authors retain copyright under Creative Commons licenses
• Often supported by universities, funders, or government mandates
• APC may be waived for some authors (low-income countries, grants)

Subscription-Based Journals:

These journals restrict access to paying subscribers. Authors generally do not pay to publish.

• Access limited to subscribers or institutions
• No APC, but may charge for color figures or excess pages
• Often carry higher impact factors or prestige
• Delays in public availability of research
• Limited citation and media reach

Key Factors to Consider When Choosing:

1. Target Audience Reach:

If your research is intended to influence global practice, guidelines, or policymaking, OA maximizes readership. Readers in resource-limited settings without institutional subscriptions can freely access your work. OA is highly recommended for Stability Studies or trial results with public health relevance.

2. Sponsor and Funder Requirements:

Many public and private sponsors now mandate OA publishing. Examples include:

• NIH (USA), Wellcome Trust, Bill & Melinda Gates Foundation
• EU Horizon 2020 and similar research initiatives
• Pharma companies promoting transparency of trial data

Check the sponsor’s publication policy before choosing a journal.

3. Budget and Publication Charges:

OA journals charge APCs ranging from $500 to $5000 depending on the journal’s impact factor and publisher. While some journals offer waivers, authors without funding may struggle with these fees. In contrast, subscription-based journals usually do not charge authors (though page/figure fees may apply).

Some hybrid journals offer both models—subscription with optional OA by paying APCs.

4. Journal Impact and Indexing:

Subscription-based journals often have longer histories and higher impact factors, making them attractive for career progression. However, many OA journals (e.g., PLOS ONE, BMC, Frontiers) are now indexed in PubMed, Scopus, and have strong citation metrics.

Whether you publish OA or not, ensure the journal is peer-reviewed and indexed in reputable databases to preserve scientific credibility.

Advantages of Open Access Publishing:

• Increased visibility and citations
• Faster dissemination of results
• Supports equity and democratization of knowledge
• Mandatory under many transparency frameworks for clinical research
• Enables public scrutiny and ethical accountability of pharma trials

Studies have shown that OA articles receive significantly more downloads and social media engagement compared to paywalled ones.

Limitations and Risks of Open Access:

• High APCs may not be affordable without grant support
• Quality varies widely across OA journals—watch for predatory publishers
• Newer OA journals may lack established impact metrics
• Peer-review timelines may be shorter, but not always transparent

To avoid predatory journals, check membership in DOAJ, COPE, and publisher reputation before submission.

When to Prefer Subscription-Based Journals:

Choose a subscription-based journal if:

• You’re targeting a high-impact, field-specific audience
• Your institution has access to that journal and broad readership
• You have no funds for APCs and no mandate for OA
• Your manuscript addresses niche regulatory issues (e.g., pharma regulatory requirements)

Comparison Table: Open Access vs Subscription

Hybrid Journals – A Middle Ground:

Many high-impact journals now offer OA options under a hybrid model. Authors can choose to publish OA by paying APCs or go the traditional route. These provide the best of both worlds—prestige and accessibility.

Examples: The Lancet, NEJM, JAMA Network Open

Best Practices for Choosing the Right Journal:

1. Match your manuscript topic with the journal scope and audience
2. Check indexing and peer review rigor
3. Evaluate APCs and funding availability
4. Ensure ethical publishing policies (COPE member, transparent fees)
5. Confirm compliance with sponsor or institutional mandates

You can also refer to publishing support resources on Pharma SOPs and follow guidelines for manuscript preparation based on validation master plans or trial protocols.

Conclusion:

There is no one-size-fits-all answer when choosing between open access and subscription-based journals. The best choice depends on your manuscript’s audience, funding support, sponsor policy, and strategic goals. Open access enhances global reach and aligns with current trends in GMP compliance transparency, while subscription journals may offer prestige and history.

Make an informed decision based on journal quality, accessibility, and your publishing priorities. A well-placed manuscript can maximize impact, citations, and influence in the pharmaceutical and clinical research community.